Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial-derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions.

References 


Articles referenced by this article (25)


Show 10 more references (10 of 25)

Citations & impact 


Impact metrics

Jump to Citations

Citations of article over time

Article citations


Go to all (58) article citations

Funding 


Funders who supported this work.

MDA/Wings Over Wall Street

    NIA NIH HHS (1)

    NIH/NINDS (2)

    NINDS NIH HHS (2)

    Parkinsons Disease Foundation, USA

      US Department of Defense (1)

      Udall Parkinson's Disease Research (1)